Skip to main content

Advertisement

Table 2 Age-adjusted incidence rates per 100,000 person-years, stratified by age and gender

From: Racial differences in six major subtypes of melanoma: descriptive epidemiology

  NHW HW Black Asian/PI Total
Melanoma in situ
 All ages 9.19 (9.11–9.28) 1.26 (1.18–1.35) 0.16 (0.13–0.20) 0.34 (0.30–0.38) 6.60 (6.54–6.66)
 <40 years 2.18 (2.12–2.24) 0.21 (0.18–0.24) 0.03 (0.02–0.05) 0.10 (0.08–0.13) 1.31 (1.27–1.34)
 40–64 years 13.97 (13.78–14.16) 1.61 (1.47–1.76) 0.19 (0.14–0.26) 0.48 (0.40–0.57) 9.82 (9.69–9.94)
 65+ years 29.35 (28.93–29.77) 5.14 (4.63–5.70) 0.67 (0.49–0.90) 1.07 (0.87–1.31) 22.72 (22.41–23.04)
 Male 10.71 (10.58–10.85) 1.22 (1.09–1.35) 0.19 (0.14–0.26) 0.35 (0.29–0.42) 7.95 (7.85–8.05)
 Female 8.33 (8.22–8.45) 1.37 (1.26–1.48) 0.15 (0.11–0.19) 0.34 (0.29–0.39) 5.77 (5.70–5.85)
Superficial spreading melanoma
 All ages 9.05 (8.96–9.13) 1.12 (1.05–1.19) 0.15 (0.12–0.18) 0.31 (0.27–0.35) 6.18 (6.13–6.24)
 <40 years 3.35 (3.27–3.42) 0.35 (0.32–0.39) 0.04 (0.02–0.06) 0.11 (0.08–0.14) 1.96 (1.92–2.00)
 40–64 years 14.73 (14.54–14.93) 1.81 (1.66–1.97) 0.20 (0.15–0.27) 0.47 (0.39–0.56) 10.04 (9.91–10.17)
 65+ years 21.09 (20.74–21.45) 2.91 (2.53–3.33) 0.51 (0.35–0.71) 0.81 (0.64–1.02 15.93 (15.67–16.20)
 Male 10.23 (10.10–10.37) 0.98 (0.88–1.09) 0.18 (0.13–0.24) 0.34 (0.28–0.41) 7.20 (7.11–7.29)
 Female 8.27 (8.16–8.39) 1.29 (1.19–1.39) 0.13 (0.09–0.17) 0.29 (0.24–0.34) 5.49 (5.42–5.57)
Nodular melanoma
 All ages 1.80 (1.76–1.84) 0.49 (0.44–0.54) 0.06 (0.04–0.08) 0.14 (0.12–0.17) 1.30 (1.28–1.33)
 <40 years 0.38 (0.35–0.40) 0.08 (0.06–0.10) 0.01 (0.00–0.02) 0.04 (0.02–0.06) 0.23 (0.21–0.24)
 40–64 years 2.31 (2.24–2.39) 0.51 (0.43–0.60) 0.06 (0.03–0.10) 0.14 (0.10–0.19) 1.60 (1.55–1.65)
 65+ years 6.98 (6.78–7.19) 2.26 (1.92–2.65) 0.31 (0.19–0.48) 0.63 (0.47–0.82) 5.46 (5.30–5.61)
 Male 2.51 (2.45–2.58) 0.60 (0.51–0.70) 0.07 (0.04–0.12) 0.19 (0.14–0.24) 1.84 (1.80–1.89)
 Female 1.26 (1.22–1.30) 0.42 (0.36–0.48) 0.05 (0.03–0.08) 0.11 (0.08–0.15) 0.91 (0.88–0.93)
Lentigo maligna melanoma
 All ages 1.87 (1.83–1.90) 0.23 (0.19–0.27) 0.02 (0.01–0.04) 0.06 (0.05–0.08) 1.37 (1.35–1.40)
 <40 years 0.05 (0.04–0.06) 0.01 (0.00–0.01) 0.00 0.01 (0.00–0.02) 0.03 (0.03–0.04)
 40–64 years 1.83 (1.77–1.90) 0.17 (0.13–0.23) 0.01 (0.00–0.04) 0.05 (0.03–0.09) 1.26 (1.22–1.31)
 65+ years 10.11 (9.87–10.36) 1.38 (1.11–1.69) 0.16 (0.08–0.29) 0.33 (0.22–0.47) 7.69 (7.51–7.87)
 Male 2.97 (2.90–3.04) 0.33 (0.26–0.41) 0.04 (0.02–0.08) 0.09 (0.06–0.13) 2.21 (2.16–2.26)
 Female 1.05 (1.02–1.09) 0.17 (0.13–0.21) 0.01 (0.00–0.03) 0.04 (0.02–0.06) 0.77 (0.74–0.80)
Acral lentiginous melanoma, malignant
 All ages 0.21 (0.20–0.22) 0.24 (0.21–0.28) 0.19 (0.16–0.23) 0.17 (0.14–0.20) 0.20 (0.19–0.22)
 <40 years 0.04 (0.03–0.05) 0.02 (0.01–0.02) 0.02 (0.01–0.03) 0.02 (0.01–0.03) 0.03 (0.03–0.04)
 40–64 years 0.25 (0.23–0.28) 0.26 (0.20–0.32) 0.21 (0.16–0.28) 0.17 (0.13–0.23) 0.24 (0.22–0.26)
 65+ years 0.87 (0.80–0.95) 1.24 (0.99–1.54) 0.93 (0.71–1.20) 0.85 (0.67–1.07) 0.90 (0.84–0.96)
 Male 0.22 (0.20–0.24) 0.25 (0.19–0.31) 0.22 (0.16–0.30) 0.20 (0.16–0.26) 0.22 (0.20–0.23)
 Female 0.21 (0.19–0.23) 0.24 (0.20–0.30) 0.18 (0.14–0.22) 0.14 (0.11–0.18) 0.20 (0.18–0.21)
Malignant melanoma, NOS
 All ages 11.73 (11.64–11.83) 2.25 (2.14–2.36) 0.51 (0.45–0.57) 0.66 (0.60–0.72) 8.36 (8.29–8.42)
 <40 years 3.37 (3.30–3.44) 0.48 (0.44–0.53) 0.10 (0.07–0.13) 0.17 (0.14–0.21) 2.02 (1.98–2.07)
 40–64 years 17.35 (17.14–17.56) 2.98 (2.78–3.18) 0.57 (0.48–0.67) 0.83 (0.72–0.94) 12.10 (11.96–12.24)
 65+ years 35.91 (35.45–36.38) 8.46 (7.79–9.18) 2.22 (1.87–2.62) 2.42 (2.11–2.77) 27.92 (27.58–28.28)
 Male 14.63 (14.47–14.79) 2.31 (2.13–2.49) 0.63 (0.53–0.75) 0.69 (0.61–0.79) 10.68 (10.57–10.80)
 Female 9.70 (9.58–9.82) 2.30 (2.16–2.44) 0.43 (0.36–0.50) 0.64 (0.57–0.72) 6.74 (6.66–6.82)
  1. Diagnosed in the period of 1992–2011 in the SEER 13 database. In each cell, estimate (95 % CI). Rates are age-standardized using the U.S. 2000 Census population